Takeda's says pipeline can push revenue to $47 billion by 2030
Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) yesterday provided an update on its pipeline portfolio, which it says has the potential to contribute significantly to revenue growth for the company over the next decade, during its ‘Wave 1 Pipeline Opportunity’ call.
The company also shared its PTS (probability of technical success) adjusted view for fiscal year 2019-2030 revenue compound annual growth rate (CAGR) (low single-digit), as well as its goal for FY2019-FY2030 revenue CAGR (mid-single-digit), amounting to 5 trillion yen ($47 billion) by FY2030. This compares with estimated revenue of 3.2 trillion yen in the current fiscal year.
Takeda's shares, which down 6.5% this year, rose 1.2% in Tokyo trading versus a 0.9% gain in the broader market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze